Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136921 | 0.93 | KDM2B (0.44) | KDM2BHRH3PIM1CYP3A4CYP2D6 | |
| SCHEMBL4935533 | 0.93 | KDM2B (0.43) | KDM2BHRH3PIM1CYP3A4CYP2D6 | |
| SCHEMBL4933778 | 0.92 | KDM2B (0.45) | KDM2BHRH3PIM1CYP3A4CYP2D6 | |
| SCHEMBL4135879 | 0.88 | ACVR1 (0.42) | KDM2BHRH3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4136329 | 0.88 | HRH3 (0.42) | KDM2BHRH3CYP3A4CYP2C9CNR2 | |
| SCHEMBL4131497 | 0.87 | HRH3 (0.44) | KDM2BHRH3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4134644 | 0.86 | CYP2C9 (0.43) | KDM2BHRH3PIM1CYP3A4CYP2D6 | |
| SCHEMBL4931795 | 0.86 | KDM2B (0.49) | KDM2BHRH3CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4136835 | 0.84 | SCD (0.46) | KDM2BHRH3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1742761 | 0.84 | HRH3 (0.58) | KDM2BHRH3PIM1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | KDM2B 577/4885HRH3 1/4885PIM1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.